share_log

Jin Medical International | 20-F/A: Registration statement / Annual report / Transition report (Amendment)

SEC ·  Mar 20 20:10

Summary by Moomoo AI

Jin Medical International has filed Amendment No. 1 to its Annual Report on Form 20-F for the fiscal year ended September 30, 2024. The amendment primarily addresses the "Controls and Procedures" section in response to SEC staff comments and restates the company's status as an accelerated filer.Management has identified a significant weakness in internal control over financial reporting, specifically citing a lack of adequately skilled staff with U.S. GAAP knowledge. To address this, the company plans to hire additional accounting personnel, enhance financial reporting functions, and implement regular U.S. GAAP training programs for staff.As an emerging growth company with revenue below $1.235 billion, Jin Medical qualifies for reduced reporting requirements under the JOBS Act, including exemption from auditor attestation requirements under Section 404 of the Sarbanes-Oxley Act. The company maintains 156,547,100 outstanding ordinary shares as of September 30, 2024.
Jin Medical International has filed Amendment No. 1 to its Annual Report on Form 20-F for the fiscal year ended September 30, 2024. The amendment primarily addresses the "Controls and Procedures" section in response to SEC staff comments and restates the company's status as an accelerated filer.Management has identified a significant weakness in internal control over financial reporting, specifically citing a lack of adequately skilled staff with U.S. GAAP knowledge. To address this, the company plans to hire additional accounting personnel, enhance financial reporting functions, and implement regular U.S. GAAP training programs for staff.As an emerging growth company with revenue below $1.235 billion, Jin Medical qualifies for reduced reporting requirements under the JOBS Act, including exemption from auditor attestation requirements under Section 404 of the Sarbanes-Oxley Act. The company maintains 156,547,100 outstanding ordinary shares as of September 30, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 392

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
Nephros
NEPH
1.690
Innovative Eyewear
LUCY
2.948
Alcon
ALC
94.140
Kestra Medical Technologies
KMTS
24.400
Glucotrack
GCTK
0.2450
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
77%
23%
Bullish
Bearish
1521 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....